Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
ImmuneID is a precision immunology company that provides a technological platform to deliver insights into the human immune response.
Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.
Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases.
Longwood Fund has invested in 55 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Longwood Fund's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 15 different industry categories.
Among tracked funding rounds, Tome Biosciences received $213.0M in a Series A round. Longwood Fund's total known invested capital is $4.0B.
Longwood Fund's average investment size is $80.0M across its portfolio of 55 companies.
Recent Longwood Fund portfolio additions include AAVantgarde Bio, Vertero, Rectify Pharmaceuticals, Mediar Therapeutics, Verastem Oncology. These companies were founded in 2020 or later.